Tusamitamab ravtansine clinical trials
Also written SAR408701.
How each study uses tusamitamab ravtansine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 1
Sanofi (9) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Erasmus Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tusamitamab ravtansine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsTerminatedPhase 3SanofiNCT04154956Written as SAR408701
- Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCTerminatedPhase 2SanofiNCT04524689Written as SAR408701 (Tusamitamab ravtansine)
- Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsTerminatedPhase 2SanofiNCT04659603Written as tusamitamab ravtansine
- Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEATerminatedPhase 2SanofiNCT05245071Written as Tusamitamab ravtansine
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric CancerTerminatedPhase 2SanofiNCT05071053Written as Tusamitamab ravtansine (SAR408701)
- Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid TumorsCompletedPhase 1SanofiNCT03324113Written as SAR408701
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)TerminatedPhase 2SanofiNCT04394624Written as SAR408701
- Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid TumorsTerminatedPhase 1SanofiNCT05429762Written as Tusamitamab ravtansine
- Evaluation of SAR408701 in Patients With Advanced Solid TumorsTerminatedPhase 1SanofiNCT02187848Written as SAR408701
- The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT05849246Written as Tusamitamab ravtansine+Sintilimab
- INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701WithdrawnPhase 2Erasmus Medical CenterNCT05703555Written as Tusamitamab ravtansine
Codes
What other systems call tusamitamab ravtansine · ClinicalTrials.gg INT001749
- MeSH (NLM) C000720449tusamitamab ravtansineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DSS3BE2ZXNTUSAMITAMAB RAVTANSINEConfirmed FDA, NLM
- NCI Thesaurus C117229Tusamitamab RavtansineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720449 | tusamitamab ravtansine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DSS3BE2ZXN | TUSAMITAMAB RAVTANSINE | Confirmed FDA, NLM |
| NCI Thesaurus | C117229 | Tusamitamab Ravtansine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.